» Articles » PMID: 34582790

High Prevalence of Multilocus Pathogenic Variation in Neurodevelopmental Disorders in the Turkish Population

Abstract

Neurodevelopmental disorders (NDDs) are clinically and genetically heterogenous; many such disorders are secondary to perturbation in brain development and/or function. The prevalence of NDDs is > 3%, resulting in significant sociocultural and economic challenges to society. With recent advances in family-based genomics, rare-variant analyses, and further exploration of the Clan Genomics hypothesis, there has been a logarithmic explosion in neurogenetic "disease-associated genes" molecular etiology and biology of NDDs; however, the majority of NDDs remain molecularly undiagnosed. We applied genome-wide screening technologies, including exome sequencing (ES) and whole-genome sequencing (WGS), to identify the molecular etiology of 234 newly enrolled subjects and 20 previously unsolved Turkish NDD families. In 176 of the 234 studied families (75.2%), a plausible and genetically parsimonious molecular etiology was identified. Out of 176 solved families, deleterious variants were identified in 218 distinct genes, further documenting the enormous genetic heterogeneity and diverse perturbations in human biology underlying NDDs. We propose 86 candidate disease-trait-associated genes for an NDD phenotype. Importantly, on the basis of objective and internally established variant prioritization criteria, we identified 51 families (51/176 = 28.9%) with multilocus pathogenic variation (MPV), mostly driven by runs of homozygosity (ROHs) - reflecting genomic segments/haplotypes that are identical-by-descent. Furthermore, with the use of additional bioinformatic tools and expansion of ES to additional family members, we established a molecular diagnosis in 5 out of 20 families (25%) who remained undiagnosed in our previously studied NDD cohort emanating from Turkey.

Citing Articles

Functional analysis of a novel homozygous missense gene variant: a case report with dual genetic diagnoses.

Zhu Y, Wu K, Wen H Front Pediatr. 2025; 13:1494530.

PMID: 39995896 PMC: 11847699. DOI: 10.3389/fped.2025.1494530.


The Golgi complex governs natural killer cell lytic granule positioning to promote directionality in cytotoxicity.

Pedroza L, van den Haak F, Frumovitz A, Hernandez E, Hegewisch-Solloa E, Orange T Cell Rep. 2025; 44(1):115156.

PMID: 39813120 PMC: 11844255. DOI: 10.1016/j.celrep.2024.115156.


GREGoR: Accelerating Genomics for Rare Diseases.

Dawood M, Heavner B, Wheeler M, Ungar R, LoTempio J, Wiel L ArXiv. 2025; .

PMID: 39764392 PMC: 11702807.


The impact of the Turkish population variome on the genomic architecture of rare disease traits.

Coban-Akdemir Z, Song X, Ceballos F, Pehlivan D, Karaca E, Bayram Y Genet Med Open. 2024; 2:101830.

PMID: 39669594 PMC: 11613692. DOI: 10.1016/j.gimo.2024.101830.


BICEP: Bayesian inference for rare genomic variant causality evaluation in pedigrees.

Ormond C, Ryan N, Cap M, Byerley W, Corvin A, Heron E Brief Bioinform. 2024; 26(1).

PMID: 39656772 PMC: 11645550. DOI: 10.1093/bib/bbae624.


References
1.
Bizzotto S, Dou Y, Ganz J, Doan R, Kwon M, Bohrson C . Landmarks of human embryonic development inscribed in somatic mutations. Science. 2021; 371(6535):1249-1253. PMC: 8170505. DOI: 10.1126/science.abe1544. View

2.
Alhaddad B, Schossig A, Haack T, Kovacs-Nagy R, Braunisch M, Makowski C . PRUNE1 Deficiency: Expanding the Clinical and Genetic Spectrum. Neuropediatrics. 2018; 49(5):330-338. DOI: 10.1055/s-0038-1661396. View

3.
Fromer M, Moran J, Chambert K, Banks E, Bergen S, Ruderfer D . Discovery and statistical genotyping of copy-number variation from whole-exome sequencing depth. Am J Hum Genet. 2012; 91(4):597-607. PMC: 3484655. DOI: 10.1016/j.ajhg.2012.08.005. View

4.
Pehlivan D, Karaca E, Aydin H, Beck C, Gambin T, Muzny D . Whole-exome sequencing links TMCO1 defect syndrome with cerebro-facio-thoracic dysplasia. Eur J Hum Genet. 2014; 22(9):1145-8. PMC: 4135405. DOI: 10.1038/ejhg.2013.291. View

5.
Lamsal R, Zwicker J . Economic Evaluation of Interventions for Children with Neurodevelopmental Disorders: Opportunities and Challenges. Appl Health Econ Health Policy. 2017; 15(6):763-772. PMC: 5701958. DOI: 10.1007/s40258-017-0343-9. View